Promotional literature

[Guest guest]

Respected members,

US FDA

recommended principles of "Good Reprint Practices":

Organizational

publications which are peer-reviewed and not funded by the manufacturers

of the product in the manuscript.

The

manufacturer should not influence directly, or any individual involved in

the writing, editing or publishing of the scientific information.

The

information in the scientific or medical journal article or reference

publications should not be false or misleading and should be derived from

adequate and well-controlled clinical investigations.

The

information should not pose a significant risk to the public health.

Publications

which do not qualify for dissemination to healthcare professionals include

letters to editors, abstracts of publications, results of Phase I trials

and publications without relevant investigations or data.

Scientific

information should not be presented in a form that might bias the judgment

of the physician and should be accompanied by the approved labeling of the

drug or the device.

Regards

Dr Sanjay Yallappa Choudhari

JR2,Dept of Pharmacology

GMC, Nagpur